Dr. QI Rong

Full Professor, Doctoral Supervisor in Pharmacology

QIRong, Principal Investigatorof State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University;Principal Investigator of The National Health Commission Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptide, Peking University.

Contact Information

Telephone：(010)-8280 2822

Fax：(010)-8280 2822

Email：ronaqi@bjmu.edu.cn

Research Field

Molecular Cardiovascular Pharmacology

Research Interests

1. New targets for cardiovascular disease intervention.

2. Discovery of drugs that delay aging and promote tissue regeneration, as well as their intervention effects on cardiovascular diseases.

3. In vivo delivery and clinical translational research of cardiovascular drugs.

Joint Academic Societies

Member ofthe Chinese Pharmacological Society(Biochemical and Molecular Pharmacology Committee;Cardiovascular Pharmacology Committee; Epigenetic Pharmacology Committee; Traditional Chinese Medicine PharmacologyCommittee).Member of the Cardiovascular and Cerebrovascular Committee of the Beijing Pharmacological Society.Member of the China Association of Chinese Medicine(Deputy Director of the Antrodia cinnamomea Committee; Microcirculation Committee).

Educational and work experience（Sort in reverse chronological order）

2024/09 –, Department of Pharmacology, School of Basic Medical Sciences, Peking University, Deputy Director (Managementof Research and Postgraduate Training)

2023/04 – 2023/09, Cardiovascular Translational Research Center, National University of Singapore, Visiting Professor.

2021/01 –, Department of Pharmacology, School of Basic Medical Sciences, Peking University, FullProfessor, Doctoral Student Supervisor.

2018/08 – 2020/12, Institute of Cardiovascular Diseases, Peking University, Principal Investigator, Doctoral Student Supervisor.

2016/10 – 2016/12, Institute of Polymer Science, National Taiwan University / Taiwan National Health Research Institutes, Visiting Professor.

2010/08 – 2018/07, Institute of Cardiovascular Diseases, Peking University, Associate Research Fellow, Master’sStudent Supervisor.

2004/08 – 2010/07, Institute of Cardiovascular Diseases, Peking University, Assistant Research Fellow.

2008/05 – 2010/01, University of Michigan School of Medicine, USA, Postdoctoral Research Fellow.

2001/09 – 2004/07, China Pharmaceutical University, Doctor of Pharmaceutical Science.

1998/09 – 2001/07, Shenyang Pharmaceutical University, Master of Pharmaceutical Science.

Teaching Courses

Pharmacology, teaching for undergraduates.

Circulatory System Integration Course,teaching for Eight-Year M.D./Ph.D. Program.

Advances in Pharmacological Research,teaching for Postgraduates.

Research team

Team photos

Resume of Dr. DIChang (Technician)

Chang Di, Ph.D., is a senior technician in the Department of Pharmacology, School of Basic Medical Sciences, Peking University. Received a Doctor of Science degree from the Institute of Zoology, Chinese Academy of Sciences in 2017, and conducted postdoctoral research at the School of Pharmaceutical Sciences, Peking University from 2017 to 2020.The research direction focuses on exploring the pathological changes of ion channels in cardiovascular diseases and conducting drug screening based on ion channel targets. The research results were published in journals such as Br J Pharmacol and Int J Mol Sci. She is currently a member of the Youth Committee of the Cardiovascular Professional Committee of the Chinese Pharmacological Society. She successively won the first prize for outstanding young papers at the Third Oriental Pharmacology Forum, Outstanding Award of the 15th Beijing Pharmacological Society Young Scientists Forum, Third Prize of the 22nd Young Teachers' Basic Teaching Skills Competition of the School of Basic Medical Sciences, Peking University First Prize of Creator Camp of "Peking University Pharmacology" in the Department of Pharmacology, etc.

Resume of Dr. LUJian (Postdoc.)

Jian Lu graduated from the School of Pharmacy of East China University of Science and Technology in 2023 with a Doctor of Agriculture degree and was awarded the title of Outstanding Graduate of Shanghai. His research direction is to study the development and toxic effects of drugs on the cardiovascular system based on zebrafish and cell models.

Research achievements

1. LeadingResearch Projects(Sort in reverse chronological order)

（1）National Natural Science Foundation of ChinaProject: Inotodiol inhibits the proliferation and migration of smooth muscle cells by regulating calpain 2, thereby slowing down vascular remodeling in pulmonary arterial hypertension,2025/01-2028/12.

（2）Beijing Natural Science FoundationProject: The role and mechanism of hydroxymethylbilane synthase in inhibiting mitochondrial oxidative stress injury and preventing myocardial hypertrophy,2023/01-2025/12.

（3）National Natural Science Foundation of ChinaProject: Study on the role of Inotodiol in regulating hydroxymethylbilane synthase to improve mitochondrial function and quality control, promoting myocardial energy metabolism and anti-myocardial hypertrophy,2022/01-2025/12.

（4）The National Key Research and Development Program Project of the Ministry of Science and Technology:Study on the intervention effects of Intelligent Polyurethane Material-encapsulated cycloastragenol alcohol-prepared nanoparticles, artificial blood vessels, self-healing hydrogel and 3D printed hydrogel structures on abdominal aortic aneurysms,2020/12-2024/11.

（5）National Natural Science Foundation of ChinaProject,Study on the anti-inflammatory effect of naringenin on non-alcoholic fatty liver disease through NF-kB/NLRP3 pathway,2019/01-2021/12.

（6）National Natural Science Foundation of ChinaProject, Study on the anti-myocardial fibrosis effect of Antrodia cinnamomea and its monomers by regulating aldehyde dehydrogenase 2,2018/01-2021/12.

（7）Ministry of Science and Technology 973Project(2015CB932100): Key members of the sub-project: Research on the transport mechanism and clinical translation of oral nanomedicines for poorly soluble drugs,2015/07-2019/08.

（8）National Natural Science Foundation of ChinaProject,Study on the lipid-lowering and anti-atherosclerotic effects and mechanisms of the aromatic herb Dracocephalum moldavica,2014/01-2017/12.

（9）National Natural Science Foundation of ChinaProject,Study on the efficacy and mechanism of promoting the oral administration of probucol by constructing a nano-drug delivery system with pegylated dendritic polymer carriers,2013/01-2016/12.

（10）Ministry of Science and Technology 973Project(2009CB930300):Key members of the sub-project:Applied basic research on improving the efficacy of poorly soluble drugs by nanotechnology,2009/01-2013/12.

（11）The Ministry of Education's Start-up Fund for Returned Overseas Scholar:The application of polyethylene glycol-modified dendritic molecular polymer nano-gene vectors in the gene therapy research of hyperlipidemia caused by single-gene defects,2012-2014.

（12）National Natural Science Foundation of ChinaProject:The application of polyethylene glycol-modified dendritic molecular polymer nano-gene vectors in the gene therapy research of hyperlipidemia caused by single-gene defects,2010/01-2012/12.

（13）National Natural Science Foundation of ChinaProject:The application of dendritic nanomaterials as non-viral gene vectors in the basic research of hyperlipidemia and atherosclerosis,2006/01-2008/12.

2. List of Representative Papers Published as aCorresponding Author(Sort in reverse chronological order)

(1)Hu WP, Cai ZY, Li QL, Zhang T, Chu XY, Wang C, Zhang QY, Qi R*. PP2Acα Deficiency in Vascular Smooth Muscle Cells Accelerates Aortic Aneurysm and Dissection by Regulating KLF4 Phosphorylation and Ubiquitination. Advanced Science, 2025, accepted. (IF="14.3," Q1)

(2)Ma YH#, Wang YX#, Anwaier G#, Tuerdi N, Wu YC, Huang YY, Qin BY, Ma HY, Zhang Q, Wu DL, Zeng KW, Qi R*. Cinnamomea Triterpenoids Attenuate Cardiac Hypertrophy via the SNW1/RXR/ALDH2 axis, Redox Biology, 2024 Nov 19;78:103437. doi: 10.1016/j.redox.2024.103437. (IF="10.6," Q1)

(3)Ma ZJ, Qiu YK, Yu ZW, Song TT, Hu YT, Peng AK, Qi R*. Natural Small Molecule Hinokitone Mitigates NASH Fibrosis by Targeting Regulation of FXR-mediated Hepatocyte Apoptosis. J Advanced Research, 2024 Dec 13:S2090-1232(24)00593-9.(IF="11.4, Q1)

(4)Chen D#, Song TT#, Liu Y#, Wang Y, Qin BY, Zhang QY, Hu WP, Zhou XQ, Qi R*. Effective Hydrogel Vascular Patch Dual-Loaded with Cycloastragenol Nanostructured Lipid Carriers and Doxycycline for Repairing Extravascular Injury in Abdominal Aortic Aneurysm.Adv Healthc Mater, 2024 Dec 20:e2402497. doi: 10.1002/adhm.202402497.(IF="11.09," Q1)

(5)Shih YT, Cheng KC, Ko YJ, Lin CY, Wang MC, Lee CI, Lee PL, Qi R*, Chiu JJ*, Hsu SH*.3D-Printed proangiogenic patches of photo-crosslinked gelatin and polyurethane hydrogels laden with vascular cells for treating vascular ischemic diseases.Biomaterials. 2024 Apr 30;309:122600. doi: 10.1016/j.biomaterials.2024.122600.(IF="12.8," Q1)

(6)Liang HJ, Zhang QY, Hu YT, Liu GQ,Qi R.Hypertriglyceridemia: A Neglected Risk Factor for Ischemic Stroke?J Stroke. 2022 Jan;24(1):21-40. doi: 10.5853/jos.2021.02831.Review.

(7)Hu R, Liu S, Anwaier G, Wang Q, Shen W, Shen Q, Qi R*. Formulation and intestinal absorption of naringenin loaded nanostructured lipid carrier and its inhibitory effects on nonalcoholic fatty liver disease. Nanomedicine-NBM. 2021 Feb;32:102310. doi: 10.1016/j.nano.2020.102310. Epub 2020 Oct 24.

(8)Wang Q, Ou Y, Hu G, Wen C, Yue S, Chen C, Xu L, Xie J, Dai H, Xiao H, Zhang Y, Qi R*. Naringenin attenuates nonalocholic fatty liver disease by downregulating NLRP3/NF-κB pathway in mice. Br J Pharmacol. 2020 Apr;177(8):1806-1821. doi: 10.1111/bph.14938.

(9)Chen C, Wang Y, Cao Y, Wang Q, Anwaier G, Zhang Q, Qi R*. Inhibitory effects and mechanism of probucol on elastase-induced abdominal aortic aneurysm in mice. Br J Pharmacol. 2020 Jan;177(1):204-216. doi: 10.1111/bph.14857.

(10)Wang YX, Chen C, Wang QY, Cao YN, Xu L, Qi R*. Inhibitory Effects of Cycloastragenol on Abdominal Aortic Aneurysm and its Related Mechanisms. Br J Pharmacol. 2019 Jan;176(2):282-296. doi: 10.1111/bph.14515.

3. List of Authorized Patents (Sort in reverse chronological order)

(1) Qi Rong, Zhang Qingyi. Use of Kaurane Extract in the Preparation of Products for Abdominal Aortic Aneurysm Treatment, ZL 2023 1 0584879.8. Filed on May 23, 2023, authorized on October 29, 2024.

(2) Qi Rong, Qiu Yingkun, Peng Ankang, Wang Anyi, Yue Shanshan. Use of Kaurane Extract in the Preparation of Products for Non-Alcoholic Fatty Liver Disease Treatment, ZL 2019 1 1255818.7, authorized in June 2022.

(3) Qi Rong, Huang Yanbin, Zhang Xing. Use of HPMC and Isonicotinamide Cocrystal in the Preparation of Drugs for Prevention and Treatment of Abdominal Aortic Aneurysm, ZL 2020 1 0063292.9, authorized in March 2021.

(4) Qi Rong, Hu Rui. Naringenin Nanostructured Lipid Carriers and Their Preparation Method and Application, ZL 2020 1 0038269.4, authorized in December 2020.

(5) Qi Rong, Wang Yunxia. Use of Cycloastragenol in the Preparation of Drugs for Inhibiting Abdominal Aortic Aneurysm, ZL 2017 1 0105881.7, authorized in May 2020.

(6) Qi Rong, Chen Cong. Use of Naringenin, Naringenin Nanoliposomes and Their Preparation Method and Application, ZL 2016 1 0353469.2, authorized in July 2019.

(7) Qi Rong, Xu Lu, Nu'erbiye·Tuerdi, Cheng Sida. Protective Effect of Antrodia cinnamomea and Its Monomer Lanostane 32 on Non-Alcoholic Fatty Liver Disease and the Mediating Role of ALDH2, Taiwan, China Patent, I629991, authorized in July 2018.

Graduate Student Supervision

1.Doctoral/Master's Students (Including joint training program)

Anhui Wang

Research direction:Myocardial infarction and cardiac regeneration

Email：wah321@pku.edu.cn

Yingjie Li

Research direction: G4 structure of NOP56 and targeted drug development

Email：liyingjiecuihuimei@163.com

Boyang Qin

Research direction: Cardiac injury and aging

Email：603779536@qq.com

Tiantian Song

Research direction: Liver injury, repair and regeneration

Email：tts1012@163.com

Chang Wang

Research direction: Utilizing EHT to study myocardial injury and repair

Email：changwangbj02@gmail.com

Rui Wang

Research direction: Research on novel targets and therapeutics for intervening in cardiac remodeling

Email：2110305320@stu.pku.edu.cn

Dexing Kong

Research direction: Novel targets and therapeutics for intervening in vascular remodeling in pulmonary arterial hypertension

Email：13408764727@163.com

Jishuo Lin(Joint training)

Research direction: Construction of the drug delivery system and intervention ofliver diseases

Email：17590930987@qq.com

Yicai Geng(Joint training)

Research direction: Pharmaceutical research based on traditional Chinese medicine nano-enzyme technology

Email：19872021053@163.com

Graduated Doctoral Students

Yin Tang（Associate Supervisor）

Yingchun Han（Associate Supervisor）

Yunan Wang（Associate Supervisor）

Qingyi Zhang

Haoyue Ma

Weipeng Hu

Yinghua Ma

Graduated Master's Students(Including joint training program)

Wenwen Shen, Maomao Yu, Lu Xu, Yini Cao, Cong Chen, Yunxia Wang, Qinyu Wang, Ankang Peng, Shamuha · Bahetibieke, Zejiang Ma.

(Joint training) Qian Ma, Hanran Zhang, Yanzhi Li, Guan Lian, Wanli Shen, Xuehui Zhang, Nu'erbiye · Tuerdi, Gulinigaer · Anwaier, Shu Liu, Xing Zhang, Asiya · Baiyisaiti, Rui Hu, Shanshan Yue, Du Chen, Ying Wang.